Dermatitis Clinical Trials

221 recruitingLast updated: July 25, 2026

There are 221 actively recruiting dermatitis clinical trials across 55 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include New York, New York, United States, Los Angeles, California, United States, Miami, Florida, United States. Updated daily from ClinicalTrials.gov.


Dermatitis Trials at a Glance

221 actively recruiting trials for dermatitis are listed on ClinicalTrialsFinder across 6 cities in 55 countries. The largest study group is Not Applicable with 49 trials, with the heaviest enrollment activity in New York, Los Angeles, and Miami. Lead sponsors running dermatitis studies include Pfizer, Sanofi, and National Institute of Allergy and Infectious Diseases (NIAID).

Browse dermatitis trials by phase

Treatments under study

About Dermatitis Clinical Trials

Looking for clinical trials for Dermatitis? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dermatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dermatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 221 trials

Recruiting
Phase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Atopic DermatitisDermatitis AtopicAtopic Dermatitis, Unspecified
Pfizer150 enrolled1 locationNCT06899204
Recruiting
Phase 1

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

Atopic Dermatitis
Bambusa Therapeutics99 enrolled10 locationsNCT07239947
Recruiting
Phase 1

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Healthy ParticipantsAtopic Dermatitis
Pfizer119 enrolled5 locationsNCT06564389
Recruiting
Phase 3

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Atopic Dermatitis
Pfizer500 enrolled37 locationsNCT06807281
Recruiting
Phase 1

A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis

Dermatitis Atopic
Novartis Pharmaceuticals63 enrolled1 locationNCT07604324
Recruiting
Phase 2

Effects of Treatments on Atopic Dermatitis

DermatitisEczemaSkin Diseases+2 more
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)130 enrolled1 locationNCT01631617
Recruiting

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
National Institute of Allergy and Infectious Diseases (NIAID)10,000 enrolled1 locationNCT06732414
Recruiting
Phase 2

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Atopic Dermatitis
UCB Biopharma SRL160 enrolled68 locationsNCT07277660
Recruiting
Phase 3

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Atopic Dermatitis
Organon and Co180 enrolled46 locationsNCT07265479
Recruiting

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Atopic DermatitisPsoriasisPrimary Immunodeficiency+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT04864886
Recruiting

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

Atopic DermatitisEczema
National Human Genome Research Institute (NHGRI)530 enrolled1 locationNCT00605878
Recruiting
Phase 3

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
Nektar Therapeutics510 enrolled1 locationNCT07711418
Recruiting

Sodium in the Skin and Atopic Dermatitis

Atopic DermatitisEczema
University of California, San Francisco90 enrolled2 locationsNCT06998446
Recruiting

Skin Microbial Ecology in Atopic Dermatitis

HealthyAtopic DermatitisPsoriasis
University of Rochester240 enrolled1 locationNCT04170244
Recruiting
Phase 1

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

Atopic Dermatitis
Bambusa Therapeutics237 enrolled14 locationsNCT06808477
Recruiting
Phase 2

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Atopic Dermatitis
Apogee Therapeutics, Inc.350 enrolled63 locationsNCT07003425
Recruiting

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

Atopic DermatitisEczema
Pfizer183 enrolled30 locationsNCT05689151
Recruiting
Phase 2

A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis
Jiangsu vcare pharmaceutical technology co., LTD120 enrolled1 locationNCT07598383
Recruiting
Phase 2

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Atopic Dermatitis
Hoffmann-La Roche120 enrolled24 locationsNCT07223697